The impact of integrase inhibitors on steatosis and fibrosis biomarkers in persons with HIV naive to antiretroviral therapy.

ABSTRACT:

Background

Non-alcoholic Fatty Liver Disease (NAFLD) has a high prevalence among persons with HIV infection. Since Integrase Strand Transfer Inhibitors (INSTIs) are used worldwide and have been associated with weight gain, we must determine their effect in the development of NAFLD and Non-alcoholic Steatohepatitis (NASH) in these patients. The aim of this study was to explore the impact of INSTIs on variation of liver steatosis and fibrosis in the ART-naïve person with HIV, using Hepatic Steatosis Index (HSI), Fibrosis-4 Index (FIB-4), BARD score and NAFLD Fibrosis Score (NFS).

Methods

We performed a monocentric, retrospective cohort study in ART-naïve persons with HIV that initiated INSTI based regimens between December 2019 and January 2022. Data was collected at baseline,

SUBMITTER: Fernandes SR 

PROVIDER: S-EPMC10464196 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature